- Khan, O.A. and Dhib-Jalbut, S.S. Neutralizing antibodies to interferon ß-1b in MS patients are cross-reactive. Neurology 1998; 51:1698-1702.
- Cohen, J.A. et al., Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders. Journal of Neuroimmunology 1999; 98:29-36.
- Bertolotto, A. et al., Interferon ß neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 2000; 48:95-100.
- Rudick, R. et al., Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 1998; 50:1266-1272.
- Bethoux, F.A. and Rudick, R.A. Use of an Assay for IFNß Neutralizing Antibodies in a Large MS Center: Impact on Treatment Decisions. Neurology 2000; 54(Suppl3):A58.
- The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta 1-b: Experience during the first three years. Neurology 1996; 47:889-894.
- King, J. et al., Long-term efficacy of interferon-beta 1a (Rebif®) in relapsing-remitting MS: 4-year results of the PRISMS study. Presented by M. Freedman at the American Academy of Neurology 52nd Annual Meeting, San Diego, USA, 29 April-6 May 2000.
